Mer­ck dou­bles down on Sky­hawk's tech to drug RNA, promis­ing $600M per au­toim­mune, meta­bol­ic tar­get

Ear­ly col­lab­o­ra­tions with big-name part­ners lent Sky­hawk Ther­a­peu­tics both the en­dorse­ments and the cap­i­tal to pur­sue a small mol­e­cule plat­form for drug­ging RNA. And they …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER